sur Novigenix AI
Novigenix AI Launches First AI-Powered Immune Intelligence Platform
Novigenix AI has been officially launched as a spin-out from Novigenix SA, aimed at revolutionizing precision medicine through AI-powered immune intelligence. The new company focuses on commercializing the LITOSeek® platform, an AI-enabled tool designed to understand systemic immune responses, offering insights for therapy development and patient care.
The separation allows Novigenix's colorectal cancer screening business to operate independently, while Novigenix AI targets the global biopharma and precision medicine markets. The LITOSeek® platform helps address therapy development challenges by providing actionable insights from blood samples.
With its ISO 13485 certification, LITOSeek® integrates advanced machine learning to offer real-time tracking of immune health and therapy responses, enhancing clinical trial operations. Novigenix AI's launch is bolstered by proven commercial success, with an eye on expanding to autoimmune and neurological diseases.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Novigenix AI